Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced dosing of the first patient in its Phase 1/2 clinical trial of NRTX-1001 cell therapy in adults with drug-resistant bilateral mesial temporal lobe epilepsy (MTLE). MTLE is the most common type of epilepsy in adults and is characterized by seizures originating primarily in the hippocampus from either one hemisphere of the brain (unilateral) or both hemispheres (bilateral).
Dr. Cory Nicholas is the UCSF founder. We congratulate him.